Current Report Filing (8-k)
January 21 2020 - 12:56PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 21, 2020
H-CYTE,
INC.
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
001-36763
|
|
46-3312262
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
201
E Kennedy Blvd Ste 700
Tampa,
FL
|
|
33602
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (844) 633-6839
Copies
to:
Arthur
S. Marcus, Esq
Sichenzia
Ross Ference LLP
1185
Avenue of the Americas
37th
Floor
New
York, New York
10036
(212) 930-9700
(212)
930-9725 (fax)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act: Common Stock
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
ITEM 7.01 Regulation
FD Disclosure
On
January 21, 2020, H-Cyte, Inc. (the “Company”) issued a letter to its shareholders. A copy of the letter is
attached hereto and incorporated by reference in its entirety as Exhibit 99.1.
ITEM
9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
H-CYTE,
Inc.
|
|
|
|
|
|
Date:
January 21, 2020
|
By:
|
/s/
Jeremy Daniel
|
|
|
|
Jeremy
Daniel
|
|
|
|
Chief
Financial Officer
|
H CYTE (QB) (USOTC:HCYT)
Historical Stock Chart
From Mar 2024 to Apr 2024
H CYTE (QB) (USOTC:HCYT)
Historical Stock Chart
From Apr 2023 to Apr 2024